Deutsche Bank AG Sells 323,485 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Deutsche Bank AG reduced its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 37.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 531,197 shares of the company's stock after selling 323,485 shares during the period. Deutsche Bank AG owned approximately 0.70% of Nurix Therapeutics worth $10,008,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at $2,337,000. Brevan Howard Capital Management LP acquired a new position in Nurix Therapeutics during the fourth quarter valued at $405,000. Bank of America Corp DE lifted its stake in Nurix Therapeutics by 9.3% in the 4th quarter. Bank of America Corp DE now owns 150,935 shares of the company's stock worth $2,844,000 after acquiring an additional 12,811 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Nurix Therapeutics during the 4th quarter worth about $164,000. Finally, Ameriprise Financial Inc. grew its stake in Nurix Therapeutics by 111.1% during the 4th quarter. Ameriprise Financial Inc. now owns 32,152 shares of the company's stock valued at $606,000 after acquiring an additional 16,921 shares in the last quarter.

Nurix Therapeutics Stock Up 6.6%

NASDAQ NRIX traded up $0.63 during trading on Tuesday, hitting $10.14. The company's stock had a trading volume of 1,409,430 shares, compared to its average volume of 880,923. The firm has a 50 day moving average price of $10.97 and a 200 day moving average price of $16.70. The firm has a market cap of $773.03 million, a P/E ratio of -3.51 and a beta of 2.23. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period in the previous year, the business posted ($0.76) EPS. On average, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $382,092.92. The trade was a 15.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider now owns 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NRIX. Stifel Nicolaus reduced their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Needham & Company LLC restated a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Morgan Stanley raised their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. Stephens restated an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, Leerink Partnrs upgraded shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.